The Paperwork Problem Nobody's AI Has Solved
Aerospace's fragmented certification landscape is a procurement risk that ISO 42001 and EU AI Act conformity obligations are built to catch, if buyers ask.
Find here all our blog posts tagged with: EU AI Act.
The Assurance Gap Agentic AI Exposes Isn't Aviation's Alone
Agentic AI breaks the deterministic testing model behind DO-178C, and the same structural gap is emerging across ISO 42001, EU AI Act, and FDA regimes.
Two Curves, One Decision: Agentic AI's Control Authority Is Outrunning Its Oversight
Industrial operators are handing agentic AI direct control authority faster than monitoring tools can verify it, and buyers need a risk tier to tell the two apart.
When AI Agents Reach for the Controls
Anthropic's new agent-to-machine standard collapses the gap between AI recommendation and AI action, raising the stakes for industrial verification.
Agentic AI Is Outrunning Aviation's Security Testing Playbook
Drone swarms and other agentic systems are entering aviation and defense procurement faster than security testing methods built for passive software can assess them.
Agentic AI in Clinical Trials Isn't Exempt From High-Risk Classification
Agentic AI tools for trial design look administrative, but EU AI Act and MDR overlap rules can pull them into conformity assessment regardless of vendor intent.
The EU AI Act Delay Buys Time, Not Cover
Extended EU AI Act deadlines and product-safety carve-outs shift industrial AI risk onto existing machinery and quality regimes, not away from scrutiny.
Three Regulators, Three Different Bets on AI Medtech
The EU, the US, and China are sequencing AI device oversight in opposite orders, and compliance leaders need to plan for all three.
The Change-Control Gap Between MDR and the AI Act
Predetermined change control plans reveal the specific reconciliation gap between MDR/IVDR certification and EU AI Act obligations for adaptive medical algorithms.
The Grid Is Getting a New Operator, and It Isn't Human
AI systems are shifting from consuming grid power to making real-time dispatch decisions, and that reclassification changes who is accountable when something goes wrong.
The Black Box Analogy Only Works With an NTSB Behind It
Nvidia's push for AI agent flight recorders borrows aviation's most visible artifact while skipping the investigation infrastructure that makes it useful.
Clinical Decision Support AI: Cleared, Not Proven
High-risk AI clinical decision support is scaling through FDA and IVDR pathways faster than its evidence base, leaving compliance leaders to close the gap regulators haven't.
When AI Stops Advising and Starts Operating the Grid
As AI shifts from analytics to closed-loop control in energy and industrial systems, validation and human-override design become the real governance test.
Decision Assurance Has No Tail Number
Aviation's directive model regulates known parts and configurations, but AI decision-making is already being governed elsewhere, with real gaps still unresolved.
Cleared Is Not Validated: The Evidence Gap Behind FDA's AI Device Count
FDA's public summaries for AI-enabled devices were built to demonstrate fairness, but their format makes that fairness nearly impossible to verify.
AI Drug Discovery's Capital Boom Sits Outside the Regulatory Perimeter, Not Ahead of It
Discovery-stage AI funding is surging, but the mismatch compliance leaders should track is structural, not a simple case of regulation lagging money.
When AI Stops Advising the Grid and Starts Running It
Closed-loop AI now actuates power infrastructure directly, and neither ISO 42001 nor current EU AI Act debates settle who governs that authority.
Functional Safety Meets AI Governance on the Plant Floor
ISO/IEC TS 22440 formalizes how AI intersects with functional safety just as EU AI Act high-risk rules and ungoverned agentic deployments collide on the factory floor.
The Grid's New Feedback Loop: AI Managing the Load AI Creates
AI-driven data center demand is pushing utilities toward AI-managed storage and dispatch, quietly expanding critical infrastructure governance exposure.
Agentic AI Is Outrunning Machine Safety Certification
Autonomous industrial and life sciences AI is now acting inside control loops that IEC 61508, EU AI Act risk tiers, and MDR/IVDR were not built to certify.
The Evidence Gap PV Automation Never Has to Close
FDA's mounting scrutiny of AI medical devices reveals evidence gaps even for cleared products, while pharmacovigilance AI faces no such test at all.
When AI Tunes the Process, Which Framework Governs the Record?
AI process control is now shaping regulated credit claims in biogas and RNG production, and no framework yet specifies who audits the machine's decision trail.
The Safety Gains Are Real. So Is the Skill You're Losing.
AI-driven hazard detection is cutting industrial incident rates while quietly eroding the human judgment regulators and insurers still assume workers have.
The Compliance Question Surrogate Models Can't Answer
AI surrogate models are replacing validated engineering and lab tools faster than ISO 42001, the EU AI Act, and FDA regimes can absorb them.
Aviation's AI Template Has a Recognition Problem
Aviation's tiered certification model is becoming AI governance's default architecture, but its unresolved cross-border recognition gap should worry regulated AI buyers just as much.
Aviation's AI Decisions Are Outrunning Its Liability Maps
Insurers are repricing aviation AI risk before liability attribution is settled, and the counterargument that human oversight still anchors accountability deserves scrutiny too.
A Recorder Is Not an Investigator
AI vendors are borrowing aviation's black box for accountability, but the metaphor skips the investigative infrastructure that actually makes it work.
The Assurance Gap Behind Every AI Autonomy Pitch
Aerospace certification data from Farnborough exposes a wider governance problem: many AI autonomy and risk-detection claims have no equivalent conformity regime at all.
Validation Travels. Workarounds Don't Scale.
Aviation shows a real difference between mutual-recognition validation and bilateral workarounds, and AI governance buyers need to know which one they're building.
AI Governance's Real Fault Line Is Classification, Not Geography
Divergence in AI rules across the US, EU, and China is driven less by geography than by conflicting definitions of what counts as a regulated AI function.
Plant-Floor AI Agents Are Closing the Loop Faster Than Governance Can Follow
Industrial AI agents are moving from advisory copilots to closed-loop actuation, and the audit infrastructure to govern them is still catching up.
The MedTech Compliance Asset Has a Shelf Life
MedTech buyers are pricing compliance documentation as a deal asset, but the standards that file is graded against are still being written.
HealthTech Buyers Are Pricing Compliance Before the Rules Agree With Each Other
Diligence teams valuing AI-enabled health devices are treating EU AI Act readiness as a settled asset, but FDA, EU, and China are still diverging on what that documentation must show.
The Compliance Evidence Layer Is Becoming Infrastructure
Open governance tooling, revised ISO 9001 rules, and national mandates are converging on one requirement: compliance evidence must be structured data, not paperwork.
Microgrids, AI Campuses, and an Untested Compliance Assumption
Bespoke AI campus microgrids are multiplying faster than anyone has tested whether their instability actually voids an AI Act or ISO 42001 file.
The Continuous-Update Trap in Medical AI Governance
FDA now lets manufacturers update AI devices without new submissions, but EU's MDR/IVDR and AI Act stack offers no equivalent, forcing a split lifecycle strategy.
The Contrail Trial Is Also an AI Act Compliance Test
Google and NATS are piloting AI contrail-avoidance forecasts inside live UK airspace, putting EU AI Act high-risk obligations to their first real operational test.
The Contrail Trial Exposes a New Kind of Aviation AI Risk
A North Atlantic contrail avoidance trial shows how AI-driven environmental claims and rerouting decisions are outrunning verification and liability frameworks.
The Other Compliance Clock for AI on the Plant Floor
As AI moves into industrial control systems, the EU Cyber Resilience Act and NIS2 impose a separate, faster-moving obligation than AI Act safety rules.
Two Defense AI Claims, Zero Independent Verifiers, One Week
KAI's in-house UAV AI verification and Safe Pro's trade-show validation show how little civil frameworks like ISO 42001 or the EU AI Act reach into defense AI assurance.
The Compliance Clock Slowed. The Physical Risk Didn't.
EU AI Act delays and carve-outs for industrial AI are widening the gap between regulatory relief and unresolved physical-world safety science.
The Missing Layer Between Airworthiness and AI Assurance
Bilateral aviation certification still works for conventional hardware, but no framework yet governs the AI and autonomous systems entering the same operational footprint.
Energy and Industrial AI: Compliance Before the Rules Are Written
With no coherent US AI framework and federal-state tension over infrastructure rules, energy and industrial operators should build to the strictest tested standard now.
The EU AI Act Extension Is Not the Relief It Looks Like
Brussels pushed back the high-risk AI Act deadline for regulated medical devices, but MDR and IVDR certification bottlenecks did not move with it.
The EU AI Act Extension Is a Delay, Not a Reprieve
The Digital Omnibus pushes the EU AI Act high-risk deadline for medical devices to August 2027, but MDR/IVDR and EMA already require the same work now.
The EU AI Act's Lighter Touch Is Not a Lighter Burden
Extended deadlines and narrower scope for industrial AI under the EU AI Act shift compliance obligations onto existing safety and quality frameworks rather than removing them.
Europe's AI Act and MDR Collide, and MedTech Wants a Rewrite
European MedTech is lobbying to revise how the EU AI Act and MDR/IVDR interact, and regulated buyers should build to the stricter combination now, not wait for the fix.
Europe's AI Act and MDR Are Being Rewritten at the Same Time
European regulators are revising the AI Act and MDR simultaneously, leaving life sciences compliance teams no stable baseline to build against.
The Extended Clock Is Not a Reprieve
The EU AI Act's delayed enforcement dates for medical device AI give sponsors more runway, but only if they use it to align MDR/IVDR and AI Act evidence now.
The EU AI Act Grace Period Is a Countdown, Not a Pause
Brussels pushed high-risk AI enforcement for medical devices to 2027 and 2028, but the multi-year MDR/IVDR build-out clock is already running.
The EU AI Act Reprieve Is a Timing Bet, Not a Pause
Digital Omnibus alignment gives AI-enabled medical devices breathing room on paper, but MDR/IVDR certification obligations have not moved and neither has the underlying risk.
Life Sciences Is Merging Two EU AI Act Obligations Into One
EU AI Act transparency rules for content marking and interaction disclosure are distinct obligations, and life sciences compliance teams keep treating them as one.
Capital Is Flowing to AI. Regulatory Science Capacity Is Not.
EU device rules, FDA benchmarking, and pharma's AI rollout share one constraint: regulators lack the evidence infrastructure to keep pace with deployment.
The Qualification Test That Redraws the AI Device Line
A new EU Court judgment on medical device qualification means AI tools built as informational or decision-support software may already sit inside MDR and IVDR scope.
Europe's Dual Certification Trap for Clinical AI
AI systems that influence clinical decisions can trigger MDR and EU AI Act obligations at once, and the Digital Omnibus timeline does not change that exposure.
The Non-Device Trap in EU Pharma AI
US pharma AI tools that avoid MDR device classification still face full exposure under the EU AI Act, GDPR, and EHDS.
The Inspection Layer's Governance Gap
Deep learning inspection tools are moving into FDA and MDR/IVDR-regulated production lines faster than the validation methods built to certify them.
The Governance Gap Behind FDA's AI Device Surge
FDA's AI-enabled device authorizations are scaling faster than lifecycle governance infrastructure, and the same gap is now stalling AI drug discovery approvals.
The FDA-EU Fork in AI-Enabled Medical Devices
FDA is building adaptive, lifecycle-based pathways for AI-enabled devices while the EU stacks AI Act obligations atop MDR and IVDR, forcing a sequencing decision now.
FDA's GenAI Framework Is Still a Draft of a Draft. That's the Opportunity.
FDA's two-axis risk framework for generative AI medical devices is not policy yet, and the October 19 comment window is the cheapest chance to shape it before it hardens.
The Comment Window That Will Define GenAI Medical Devices
FDA's open docket on generative AI medical devices is the narrow window life sciences leaders have to shape binding rules before they harden.
The FDA Is Still Asking Questions. Brussels Already Moved Its Clock Once.
FDA's open genAI comment period and the EU's already-shifted AI Act deadlines argue for building the shared lifecycle core, not betting on either jurisdiction's paperwork.
FDA's GenAI Pilot Is Ahead of Its Own Guardrails
FDA's provisional pathway for generative AI devices exposes a verification gap that output benchmarks and existing life cycle rules were not built to close.
What FDA's Tempo Pilot Actually Asks Compliance Leaders to Decide
FDA's reported Tempo pilot lets generative AI devices reach patients ahead of authorization, and the public record on how is thinner than the headline suggests.
The Blind Spot Beneath FDA's Generative AI Test
FDA's two-axis approach to generative AI devices is a familiar SaMD extension, but existing inspection data suggest most manufacturers can't yet clear the bar it sets.
The Vendor Blind Spot Now Living Inside Your Equipment
Frontier labs took weeks to notice their own models were hijacked, and that detection lag is now embedded wherever industrial vendors build on those models.
The Governance Debt Building in Drug Discovery AI
Regulatory frameworks are expanding toward AI in drug development, but the real exposure is a silent-failure risk that neither hype skeptics nor regulators are pricing in yet.
The Governance Tooling Decision Behind Agentic AI Rollouts
A new open source coalition for AI governance testing forces energy and industrial buyers to choose between proprietary control stacks and shared standards.
The Safety Case Has a Blind Spot: The Grid Behind the HAZOP Assistant
AI-augmented HAZOP validation focuses on model accuracy, but the compute and energy infrastructure the model depends on is an unaddressed safety variable.
ISO 9001's AI Update Is a Signal, Not a Substitute
ISO 9001's revision pulls AI-influenced decisions into quality documentation, but it does not replace ISO 42001, the EU AI Act, or sector-specific AI governance.
Compliance Is Becoming a Data Problem, Not a Paper One
India's mandate for machine-readable product standards previews a structural shift industrial AI buyers cannot ignore: verification against static documents will not scale.
Three Regulators, Three Clocks, One AI-Enabled Device
The EU, US, and China are each running statute ahead of certification infrastructure for AI-enabled medical devices, and manufacturers need one documentation architecture, not three.
A Journal Article Is Not a Regulatory Safe Harbor
A Nature Medicine audit framework for AI mental health tools is being framed as a de facto FDA standard, but no published mechanism makes that so.
Your Patients Are Uploading Health Data Into a Regulatory Gap
Life sciences firms building patient-facing AI tools are relying on a HIPAA and FDA perimeter that consumer health AI routinely sits outside.
The PCCP Illusion: Why US Speed Doesn't Buy EU Clearance
FDA's finalized change control pathway lets AI devices update without new submissions, but the EU AI Act demands continuous oversight that PCCPs were not built to satisfy.
The PCCP Gap: FDA Lets AI Models Change, Europe Asks Which Model You Meant
FDA's finalized change control plans let AI-enabled devices update without new submissions, but EU classification law may treat the same update as a new device.
The PCCP Window Before the AI Act Deadline Closes
IMDRF's new PCCP principles and the EU AI Act's delayed medtech deadline create a narrow window to build one change control architecture instead of two.
Pharma's AI Pipeline Is Running on Two Regulatory Clocks
Drug discovery AI is accelerating faster than either the EU AI Act or FDA's generative AI framework can stabilize, forcing pharma to classify now or re-litigate later.
The Physical AI Business Case Has a Regulatory Hole
Industrial buyers are being pitched humanoid and physical AI capability faster than the safety classification and liability frameworks needed to deploy it responsibly.
Physical AI's Safety Layer Can't Be One Vendor's Story
Regulated buyers deploying physical AI should demand safety verification independent of the vendor, matching the standard ISO 42001, the EU AI Act, and FDA/MDR pathways already set.
Physical AI Needs an Override Standard, Not a Trust Layer Brand
As AI systems actuate breakers and throttle industrial assets, buyers need a certifiable override standard, not a vendor's proprietary trust claim.
Power Ahead of the Grid, Ahead of the Rules
Gigawatt-scale AI data center power deals are outrunning both utility interconnection and AI safety regulation, leaving operators to self-govern autonomous grid control.
Chip Equipment Orders Are Writing AI Governance Nobody Has Defined Yet
Samsung and SK hynix are mandating embedded AI agents in new equipment orders faster than ISO 42001 or the EU AI Act can define what compliant industrial AI actually requires.
The Architecture Decision Pharmacovigilance AI Cannot Defer
Cross-jurisdictional data rules are forcing pharma safety teams to choose between centralized and localized AI architectures before regulators force the choice for them.
The Guidance Cannot Outrun the Model
FDA and EU regulators are structurally too slow to govern AI at the pace it changes, so life sciences compliance leaders must build internal governance now.
FDA Loosens the Data Bar. The EU Hasn't Said It Will Follow.
FDA's new real-world evidence flexibility for AI devices creates a sequencing risk for manufacturers still reconciling MDR/IVDR and EU AI Act data governance demands.
The Real Gate on Industrial AI Isn't the Model. It's the Safety Case.
As AI moves from dashboards to actuators on the plant floor, functional safety certification becomes the binding constraint on deployment, not model performance.
Machine Safety Certification Is Becoming a Stack, Not a Stamp
Industrial AI systems now need functional safety, AI governance, and sector regulation layered together, and buyers should verify each layer separately.
The Quality System Nobody Rebuilt Yet
FDA's living PCCP model for AI-enabled devices demands continuous evidence trails that most design control systems were never built to produce.
In Physical AI Deals, Telemetry Rights Are the Real Asset
Energy and industrial AI transactions increasingly hinge on whether sensor and telemetry data remain usable after closing, not on the model itself.
Two Risk Ledgers, One Autonomous Agent
Industrial AI autonomy and AI agent security are the same governance question asked from opposite ends, and only one side has drawn real investment.
The Grid Is Becoming a Control Loop, But the Case Isn't Closed
AI is moving from grid advisory to grid execution, but the pace is a bet on scaling, not a settled fact, and assurance regimes haven't caught up either way.
What You Didn't Automate Is Now a Governance Artifact
As industrial AI deployment accelerates unevenly, the decision to withhold automation is becoming as auditable as the decision to deploy it.
Aviation's Assurance Gap Is Two Problems, Not One
Aviation safety leaders are being sold a single fix for what are actually two distinct AI assurance failures, and conflating them will leave both unaddressed.
The Money Is Ahead of the Rulebook in Trial AI
Capital is flooding into AI for clinical trial conduct while regulators have yet to define what governs it, leaving sponsors exposed.
The Governance Gap in Clinical Trial Operations AI
Agentic AI is spreading through trial enrollment, monitoring, and feasibility work faster than FDA, EU AI Act, or ISO 42001 pathways built for medical devices can reach it.
Life Sciences AI Is Moving at Two Different Speeds
Diagnostic AI is clearing FDA review on schedule while AI-native drug discovery still has zero approvals, and the gap is documentation, not science.
The Deployer Question Utilities Haven't Asked
As AI takes over grid dispatch and demand response, energy and industrial firms need to determine their compliance status as AI deployers, not just adopters.
The Verification Bottleneck in Physical AI
As robot installations and physical AI deployments hit record volume, safety verification infrastructure, not the AI itself, is becoming the binding constraint on scale.
One Algorithm, Two Rulebooks: The Wearable AI Compliance Gap
FDA's looser wellness classification for AI wearables collides with the EU AI Act's stricter high-risk tiering, forcing global device makers to design for the harder standard first.
When Safety AI Stops Advising and Starts Acting
Industrial AI agents are moving from flagging safety risks to raising incidents autonomously, forcing operators to define authority limits before regulators do.
Who Owns the Compliance Layer When Vendors Acquire It
Dassault's purchase of ArisGlobal and Red Hat's open agent-safety project show two competing paths for AI governance, and industrial buyers must pick one before they scale agentic AI.
